Faculty Mentor

Dr. Elaine Vanterpool and Jea Joseph, MSIE

Download

Download Full Text (748 KB)

Description

As of 2020, there were an estimated 19.3 million new cancer cases and almost 10 million cancer deaths. Among the different types of cancers in the world, the most prevalent cancer, lung cancer, accounted for 23% of all cancer deaths (CDC) and has been relatively steady since 1999. However, by using Detection of Advanced Cancer Screening (D.A.C.S), many patients with cancer cases would receive efficient, reliable treatment in a timely manner. According to Cancer.gov, multiple participants reported being screened for cancer, “After they had ‘aged out of the recommended range for routine cancer screening”. (Dr. Moss) “We found that over screening was incredibly common. Overall, 45% to 75% of older adults were getting these tests [past the recommended age].” D.A.C.S can reduce over screening while identifying cancer cells by detecting the biomarker proteins in the patient’s bloodstream. By allowing a patient the capability to screen for the protein efficiently and quickly, they could determine whether further test and treatment are needed. Biomarker proteins shown at high levels could signify that a tumor is present in the body. Certain biomarkers may inhibit apoptosis, promote mitosis, and stimulate vessel growth of the infected cell which would induce chemoresistance. D.A.C.S. can detect these cancer assisting proteins by using antibodies in a lateral flow test. Similar to how a pregnancy test searches for the hormone hCG by having antibodies latch onto the hormone, D.A.C.S. uses lateral flow to have antibodies latch onto the biomarker proteins.

Publication Date

4-1-2025

City

Huntsville

Disciplines

Biology

Comments

Student Researchers: Vanterpool, Jones, Vanterpool, Lister, Swain, Ngoga, Redley, Nichalson, Shields, Moreno.

Using Secreted Biomarkers in the Development of the Detection of Advanced Cancer Screening System

Included in

Biology Commons

Share

 
COinS